N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]-2-propenamide
Grundinformationen
- CAS
414864-00-9- Standard-SMILES
O=C(C=Cc1cccc(S(=O)(=O)Nc2ccccc2)c1)NO- InChIKey
NCNRHFGMJRPRSK-UHFFFAOYSA-N- Summenformel
- C15H14N2O4S
- Durchschnittliche Molmasse
- 318,3 g/mol
- Monoisotopische Masse
- 318,06742811
Überblick
See also: Belinostat (annotation moved to).
Namen und Bezeichner
- Bevorzugter Name
- N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]-2-propenamide
- IUPAC
- N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
- Englischer Name
- Belinostat (PXD101)
- Summenformel
- C15H14N2O4S
- Molmasse
- 318.35
Namen und Synonyme
PDX101Belinostat (Non-Stereospecific)3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acidPX 105684PXD101;PX105684Belinostat(PXD-101)N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]-2-propenamideSCHEMBL375656CHEMBL3392649SCHEMBL29712104HMS3426E07HMS3654I17
Weitere Namen anzeigen
BelinostatPXD101CS-424PX105684NSC726630belinostaBelioMstatBENLINOSTATBelinostat-D5Rac-Belinostat
s1085AKOS026750234SB16466NCGC00263155-01Q23766508N-Hydroxy-3-(3-phenylsulfamoylphenyl)acrylamide Belinostat
Datenbank-Bezeichner
- CAS
414864-00-9- PubChem CID
- 53437714
- ChEMBL
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 1,7
- Polarare Oberfläche (TPSA)
- 104 Ų
- H-Brücken-Donoren
- 3
- H-Brücken-Akzeptoren
- 5
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 22
- Formalladung
- 0
- Komplexität
- 492
Physikochemische Eigenschaften
- Schmelzpunkt
- 142 · 142 - 145°C
- Dichte
- 1.427 · 1.427±0.06 g/cm3(Predicted)
- storage temp.
- Amber Vial, Refrigerator, Under inert atmosphere
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 8.31 · 8.31±0.10(Predicted)
- Farbe
- Off-White to Pale Orange
- Stabilität
- Light Sensitive
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- hs_code
- 29350090
Chemie und Industrie
Anwendungen
BeschreibungBelinostat is a drug which was developed by Spectrum Pharmaceuticals and is currently marketed by Onxeo as Beleodaq®. The drug, which received fast track designation by the United States Food and Drug Administration (US FDA) and was approved for the treatment of hematological malignancies and solid tumors associated with peripheral T-cell lymphoma (PTCL) in 2014, is a histone deacetylase (HDAC) inhibitor and is the third such treatment to receive accelerated approval for PTCL, the others being vorinostat (Zolinza®) and pralatrexate (Folotyn®). Although belinostat was not yet approved in Europe as of August 2014, the compound exhibits a safety profile considered to be acceptable for HDAC inhibitors–less than 25% of patients reported adverse effects and these most frequently were nausea, fatigue, pyrexia, anemia, and emesis.
VerwendenBelinostat is a novel histone deacetylase 3 selective inhibitor, which protects the β cells from cytokine-induced apoptosis.
Ergänzende Hinweise
DefinitionChEBI: A hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…